Positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4). Part II: Challenges in hit-to-lead
about
Synthesis and evaluation of a series of heterobiarylamides that are centrally penetrant metabotropic glutamate receptor 4 (mGluR4) positive allosteric modulators (PAMs)Neuroprotective and symptomatic effects of targeting group III mGlu receptors in neurodegenerative diseaseSynthesis and SAR of novel, 4-(phenylsulfamoyl)phenylacetamide mGlu4 positive allosteric modulators (PAMs) identified by functional high-throughput screening (HTS).Iterative experimental and virtual high-throughput screening identifies metabotropic glutamate receptor subtype 4 positive allosteric modulators.Solution-phase parallel synthesis and SAR of homopiperazinyl analogs as positive allosteric modulators of mGlu₄.Discovery, synthesis, and structure-activity relationship development of a series of N-4-(2,5-dioxopyrrolidin-1-yl)phenylpicolinamides (VU0400195, ML182): characterization of a novel positive allosteric modulator of the metabotropic glutamate receptAllosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discoveryAllosteric modulation of the group III mGlu4 receptor provides functional neuroprotection in the 6-hydroxydopamine rat model of Parkinson's diseaseSynthesis and SAR of a novel positive allosteric modulator (PAM) of the metabotropic glutamate receptor 4 (mGluR4).mGluR4-positive allosteric modulation as potential treatment for Parkinson's disease.Therapeutic potential of targeting group III metabotropic glutamate receptors in the treatment of Parkinson's disease.Metabotropic glutamate receptor 4 (mGlu4)-positive allosteric modulators for the treatment of Parkinson's disease: historical perspective and review of the patent literature.Recent progress on the identification of metabotropic glutamate 4 receptor ligands and their potential utility as CNS therapeutics.mGluR4 positive allosteric modulators with potential for the treatment of Parkinson's disease: WO09010455.
P2860
Q24650602-4BD956A8-8491-454E-A831-5FD399F5F474Q26995351-366858F9-A94F-4F28-82DB-386A395336BBQ34069332-C690F6F6-F8F6-488B-9265-6AA07351C1EAQ34271873-ECABD017-57D7-41A4-ABF6-5BF6A1550F08Q34673489-8DCF9C5A-9E42-493C-A339-0AF33C8A14AFQ35580900-EE62E966-4806-45CD-B66F-3E7CFC559BAFQ35952381-AF6D0DC2-0CCC-46EA-8034-1BF94E485027Q36252786-5CF6ADAA-C066-4A83-8F6A-A349AEB9360FQ37364758-B0159383-38EB-4B66-8E10-F014C5CCED6EQ37693720-6166A2A0-0181-4BAF-A254-181A1E0A455FQ37782115-47BDA18C-DB19-4E7F-A322-00B8A60F0299Q38002888-DCE46E56-FD94-4AC1-977D-710980C0403CQ38031832-34F64925-44DF-4B9F-82DB-E8EAC244CDFFQ43151764-F41959BB-4013-4671-973C-E562E7208BC2
P2860
Positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4). Part II: Challenges in hit-to-lead
description
2009 nî lūn-bûn
@nan
2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Positive allosteric modulators ...... II: Challenges in hit-to-lead
@ast
Positive allosteric modulators ...... II: Challenges in hit-to-lead
@en
Positive allosteric modulators ...... II: Challenges in hit-to-lead
@nl
type
label
Positive allosteric modulators ...... II: Challenges in hit-to-lead
@ast
Positive allosteric modulators ...... II: Challenges in hit-to-lead
@en
Positive allosteric modulators ...... II: Challenges in hit-to-lead
@nl
prefLabel
Positive allosteric modulators ...... II: Challenges in hit-to-lead
@ast
Positive allosteric modulators ...... II: Challenges in hit-to-lead
@en
Positive allosteric modulators ...... II: Challenges in hit-to-lead
@nl
P2093
P2860
P50
P1476
Positive allosteric modulators ...... II: Challenges in hit-to-lead
@en
P2093
Qingwei Luo
Richard Williams
P2860
P356
10.1016/J.BMCL.2008.11.104
P407
P577
2009-02-01T00:00:00Z